Gary L. Schaer, MD, FACC, FSCAI

Original Contribution

Comparative Analysis of Radial Versus Femoral Diagnostic Cardiac Catheterization Procedures in a Cardiology Training Program

05/15/2016

R. Jeffrey Snell , MD;

Gurpreet Singh , MD;

Gary L. Schaer , MD, FACC, FSCAI;

Neeraj Jolly , MD, DM;

Clifford J. Kavinsky , MD, PhD;

Enrique Padilla Campos , MD;

This study was conducted to evaluate the differences in the procedural variables between transradial and transfemoral access for coronary angiography, with cardiology fellows as the primary operators.

This study was conducted to...

05/15/2016

Journal of Invasive Cardiology

CME/CEU Offering: Small Vessel Stenting

06/19/2008

Brian H. Galbut , MD;

Gary L. Schaer , MD, FACC, FSCAI;

Topics: Small Vessel Stenting Faculty/Credentials: Brian H. Galbut, MD, Gary L. Schaer, MD, FACC, FSCAI Cardiac Catheterization Laboratories, Rush University Medical Center, Chicago, Illinois Learning Objectives. On completion of this...

Topics: Small Vessel Stenting ...

06/19/2008

Cath Lab Digest

Feature

CME/CEU Offering: Small Vessel Stenting

06/19/2008

Gary L. Schaer , MD, FACC, FSCAI;

Brian H. Galbut , MD;

Topics: Small Vessel Stenting ...

06/19/2008

Cath Lab Digest

Case Report

Use of Corticosteroids in the Treatment of Cholesterol Crystal Embolization after Percutaneous Transluminal Coronary
Angioplast

08/01/2008

Gary L. Schaer , MD, FACC, FSCAI;

Roy P. Venzon , MD;

David S. Bromet , MD;

ABSTRACT: Cholesterol crystal embolization is a rare but recognized complication of cardiac catheterization. While management has traditionally been supportive only, we demonstrate the successful use of corticosteroids in treatment of a...

ABSTRACT: Cholesterol crystal...

08/01/2008

Journal of Invasive Cardiology

Original Contribution

Outcomes of Unselected Recipients of Sirolimus-Eluting Stents: The Cypher¬Æ Stent U.S. Post-Marketing Surveillance Registry

02/02/2010

Peter C. Block , MD;

Hiram G. Bezerra , MD, PhD;

Emerson C. Perin , MD, PhD;

Marco A. Costa , MD, PhD;

Gary L. Schaer , MD, FACC, FSCAI;

Stanley Katz , MD, FACC;

Peter B. Berger , MD;

Eric J. Dippel , MD;

Stephen R. Ramee , MD;

Sidney A. Cohen , MD, PhD;

Mirle A. Kellett , MD;

Suzanne Britto , RN;

ABSTRACT: Objective. To examine the 1-year safety and clinical outcomes associated with the post-marketing early unselected use of sirolimus-eluting stents (SES) in the United States. Background. The safety and effectiveness of SES has been...

ABSTRACT: Objective. To examine...

02/02/2010

Journal of Invasive Cardiology

Review

Pharmacoinvasive Management of Acute Coronary Syndrome in the Setting of Percutaneous Coronary Intervention: Evidence-Based, Sit

08/01/2008

Deepak L. Bhatt , MD, MPH, FACC, FAHA, FESC, MSCAI;

Gideon Bosker , MD;

Gary L. Schaer , MD, FACC, FSCAI;

Dean J. Kereiakes , MD, FACC, FSCAI;

Jose G. Diez , MD;

Edward T.A. Fry , MD;

James J. Ferguson III, MD;

James P. Zidar , MD;

Glenn N. Levine , MD;

James E. Tcheng , MD;

Over the past decade, impressive reductions in mortality, reinfarction and length of hospital stay have been reported in large-scale studies of patients with acute coronary syndrome (ACS). Despite these advances, substantial challenges remain...

Over the past decade, impressive...

08/01/2008

Journal of Invasive Cardiology

Review

Pharmacoinvasive Management of Acute Coronary Syndrome in the Setting of Percutaneous Coronary Intervention: Evidence-Based, Sit

08/01/2008

Dean J. Kereiakes , MD, FACC, FSCAI;

Jose G. Diez , MD;

Edward T.A. Fry , MD;

James J. Ferguson III, MD;

James P. Zidar , MD;

Glenn N. Levine , MD;

James E. Tcheng , MD;

Deepak L. Bhatt , MD, MPH, FACC, FAHA, FESC, MSCAI;

Gideon Bosker , MD;

Gary L. Schaer , MD, FACC, FSCAI;

Part II of III - Continued TABLE 3 KEY (continued) 2) Unfractionated heparin(UFH) can be used as an alternative to enoxaparin. If UFH is used in the setting of PCI, activated clotting time (ACT) should be followed to achieve an appropriate...

Part II of III -...

08/01/2008

Journal of Invasive Cardiology

Review

Pharmacoinvasive Management of Acute Coronary Syndrome in the Setting of Percutaneous Coronary Intervention: Evidence-Based, Sit

08/01/2008

James J. Ferguson III, MD;

James P. Zidar , MD;

Glenn N. Levine , MD;

James E. Tcheng , MD;

Deepak L. Bhatt , MD, MPH, FACC, FAHA, FESC, MSCAI;

Gideon Bosker , MD;

Gary L. Schaer , MD, FACC, FSCAI;

Dean J. Kereiakes , MD, FACC, FSCAI;

Jose G. Diez , MD;

Edward T.A. Fry , MD;

A total of 5,225 patients were enrolled in the PARAGON B trial. Among these patients, the type of heparin used was known in 5,200 (99.5%). The median duration of therapy was 72.8 hours for UFH and 79.7 hours for LMWH. LMWH was used in about...

A total of 5,225 patients were...

08/01/2008

Journal of Invasive Cardiology